The formyl peptide (N-formyl-1-methionyl-1-leucyl-1-phenylalanine [FMLP]) receptor is involved in the activation of neutrophils and their subsequent response to chemotactic N-formylated peptides. Recently, we found that the first extracellular loop closest to the N-terminal end of the FMLP receptor exhibited the strongest ligand binding compared with that shown by other extracellular regions. By constructing amino acid substitutional variants of this domain, we have determined that residues Arg-84 and Lys-85 on this loop play major roles in ligand-binding activity. Furthermore, random rearrangement of the residues of this receptor region demonstrated that the position of these charged amino acids did not affect their involvement in ligand binding, although their presence was essential for this binding to occur. We propose that the portion of the first N-terminal extracellular loop of the FMLP receptor containing residues Arg-84 and Lys-85 contributes significantly to the active site in ligand-receptor binding. We further propose that this binding is not dependent on defined structure but rather that these charged moieties may function as important "contacts" in receptor-ligand interactions.
rhodopsin family which is similar in structure to the formyl peptide receptor. Using synthetic peptides, we found that the primary ligand-binding site of the FMLP receptor was localized to a 17-amino-acid (aa) stretch on the first extracellular loop of the N-terminal end of the receptor protein (31) , although other portions of the molecule may contribute to ligand binding. Recently, studies in which FMLP receptor chimeras were made also found that the major structural determinant for high-affinity ligand binding was localized to the first extracellular loop of the FMLP receptor (29, 30) .
In this study, in order to pinpoint the amino acid residues necessary to maintain ligand-receptor binding, we have synthesized different peptides corresponding to amino acid variations in this extracellular loop and have tested them for their involvement in ligand binding. We provide evidence that residues 84 and 85, Arg-84 and Lys-85, of this first extracellular loop of the FMLP receptor molecule contribute to the active site in formylated peptide binding to the receptor.
MATERIALS AND METHODS
Isolation of human neutrophils. Normal human neutrophils were isolated from fresh buffy coats according to the method described by De Nardin et al. (12) . The neutrophil yield from one buffy coat (-400 ml) was 1.3 x 109 to 2.8 x 109 cells, with a viability >96% as assessed by the exclusion of trypan blue stain. Immunofluorescence staining, analyzed by flow cytometry with a FACScan (Becton Dickinson), demonstrated a cell population that was greater than 99% neutrophils.
Preparation of neutrophil plasma membranes. Neutrophil plasma membranes were prepared by the methodology described by De Nardin and Genco (11) , with modifications. Neutrophils (2.0 x 109 to 2.5 x 109) were suspended in a phosphate-buffered saline lysing buffer (pH 7.2) containing 2.5 mM MgCl2, 1 mg of ovalbumin per ml, 2 mM phenylmethylsulfonyl fluoride, and 4 mM Not-p-tosyl-L-lysine chloromethyl ketone (TLCK) hydrochloride and then processed as described by Goetzl et al. (17) . The final membrane preparation was resuspended in chromatography buffer containing 1% CHAPS detergent (20 mM ethanesulfonic acid], 100 mM NaCl [pH 7.2] ). To detect potential proteolysis by neutrophil enzymes, '4C-bovine serum albumin ("5 x 10" cpm) was added to a sample aliquot of cells and subjected to the entire plasma membrane isolation procedure at both 4°C and room temperature. No proteolysis was observed at any of the steps.
Peptide synthesis. The peptides were synthesized by a solid-phase peptide synthesis methodology on an Applied Biosystems model 431A synthesizer, as described by Radel et al. (31) . The purity of the peptides was checked by amino acid analysis and protein sequencing, and purification was by highperformance liquid chromatography (HPLC).
Purification of peptides, amino acid analysis, and sequencing. Synthetic peptides were purified by HPLC (Rainin Rabbit-HP) and then analyzed for amino acid composition (Beckman System 6300 amino acid analyzer) and sequence (Applied Biosystems model 471A sequencer) according to the method described by Radel et al. (31) .
Photoaffinity ligand conjugation and radioiodination. A stable photoaffinity label (PAL) was prepared by conjugating the acetate form of the peptide FMLP-l-lysine (Sigma Chemical Co.) to the photoreactive cross-linker sulfosuccinimidyl-2-(p-azidosalicylamido)ethyl-1,3-dithiopropionate (Pierce Chemical Co.) (2) . Conjugation was carried out in aqueous medium by the method described by Wollenweber and Morrison (39). Radioiodination of the PAL preparation was carried out by a modification of the method described by Allen et al. (2) . Briefly, 100 p.g of IODO-GEN (Pierce Chemical Co.) was dissolved in 100 [l of chloroform and dried to a thin film under nitrogen in an amber vial. The PAL preparation was then added to the amber vial with 1 mCi (10 pLI) of carrier-free Na-'251 (Amersham International), and the reaction was allowed to proceed for 30 min at room temperature. The sample was purified on a Bio-Gel P-2 column (1.3 by 27 cm; 200 to 400 mesh) by elution with 20 mM NaOH buffer at a rate of 0.2 to 0.3 ml/min. Aliquots of 1.0-ml fractions were collected and analyzed for activity. All procedures involving the synthesis and purification of the PAL were performed under lightreduced conditions. Photoaffinity labeling of peptides and human neutrophil membranes. Photoaffinity labeling of the synthetic peptides and neutrophil membrane preparations were performed by the method described by Radel et al. (31) . Briefly, photoaffinity labeling was carried out at room temperature for 30 min in the dark, using 5 to 10 pmol (_10" cpm) of '25I-PAL. Covalent bonding of the label was initiated by photolysis for 5 min under long-wave UV light (Black-Ray; U-V Products Inc. "Underlined G residues indicate where glycine substitutions were madc.
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RESULTS
Synthetic peptides. A number of peptides (Table 1) were investigated for the ability to bind ligand directly and to inhibit the binding of ligand to neutrophil membrane preparations. Most of these peptides represented amino acid residue variations in the first extracellular loop near the N-terminal end of the receptor (residues 84 to 100, referred to as peptide 2), which has been shown to possess the major ligand-binding portion of the FMLP receptor molecule (31) . Also included were peptides which represented intracellular (peptide 2e) and transmembrane (peptide 2f) regions, as well as a randomized arrangement of the amino acid residues that make up peptide 2 (peptide 2d).
Ligand-peptide inhibition studies. Studies were performed to determine if ligand binding to the 68-kDa neutrophil membrane component as well as to peptide 2 was specific. Thirty-microgram samples of solubilized neutrophil membranes were photolabeled with '25I-PAL in the presence of increasing concentrations of peptide 2 and subjected to SDS-PAGE and autoradiography. Results after laser scanning densitometer analysis (Fig. IA) ligand (125I-PAL) into a neutrophil membrane protein of approximately 68 kDa (12) . Furthermore, a synthetic 17-aa peptide (peptide 2), corresponding to residues 84 to 100 in the first extracellular domain of the FMLP receptor, was the strongest inhibitor of ligand binding to this 68-kDa protein among synthetic peptides corresponding to the sequences of segments of the remaining extracellular portions of this receptor (31) . To elucidate which portion of the first extracellular loop played an important role in ligand binding, it was of interest to determine if modifying the C-terminal or N-terminal end of this 17-aa peptide altered ligand binding to the 68-kDa protein. Thirty-microgram samples of solubilized neutrophil membranes were exposed to 200-piM concentrations of the peptides, photolabeled with 125I-PAL, and subjected to SDS-PAGE and autoradiography ( Fig. 2A) . Laser scanning densitometry was employed to determine any differences in ligand binding with these peptide variants (Fig. 2B) . Peptide 2 showed a strong inhibition of ligand binding to the 68-kDa protein (81%), as previously reported (31) . Substitution of glycine residues in the C-terminal portion of the first extracel- lular domain (peptide 2b; aa residues 96 to 100) resulted in a small decrease in inhibitory activity (69%) compared with that of peptide 2 (81%), whereas glycine residue substitution in the N-terminal portion (peptide 2a; aa residues 84 to 87) resulted in a large reduction in inhibitory activity (22%).
Since it has been suggested that histidine may be necessary for FMLP binding to the receptor (36) , it also was of interest to investigate whether the histidine residue in peptide 2 (4, 16) . Our studies showed that the strongest ligand-binding activity was associated with the N-terminal portion of the first extracellular loop, of which the first two residues were charged moieties (Arg-84 and Lys-85). Furthermore, a random arrangement of peptide 2 residues (peptide 2d) unexpectedly showed a greater inhibitory activity than the parent peptide. Therefore, it was of interest to examine the contribution of charged residues to ligand binding, not only with the parent peptide sequence but also with the random peptide. Thirty-microgram samples of solubilized neutrophil membranes were again exposed to the peptides at 200-pLM concentrations, photolabeled with 125I-PAL, and subjected to SDS-PAGE and autoradiography (Fig. 3A) . Densitometric analysis (Fig. 3B) showed that substitution of Gly-84 for Arg-84 (peptide 2g; aa residue 84) resulted in a small decrease in inhibitory activity (60%) compared with the decrease when parent peptide 2 was used (78%). Glycine substitutions for both Arg-84 and Lys-85 (peptide 2h; aa residues 84 to 85) resulted in a large decrease in inhibitory activity (18%). A synthetic peptide that contained substitutions for all of the charged residues (Arg-84, Lys-85, and Lys-100) resulted in total abrogation of inhibitory activity of ligand binding to the FMLP receptor (results not shown). Furthermore, no effect on ligand binding was observed with polyamino acid controls (poly-L-arginine, poly-L-lysine, and polyglycine) at concentrations as high as 1 mM. Densitometric analysis examining glycine substitutions for the charged residues in the random peptide (Fig. 4) showed that a single substitution of a glycine for the arginine residue (peptide 2i) resulted in a decrease in inhibitory activity (83%) compared with that in peptide 2d (94%). Inhibitory activity was completely lost when glycines were substituted for the arginine and both lysines (peptide 2j). The same effects seen with the random peptide were found when peptide 2 residues were arbitrarily arranged in a second "random" peptide (results not shown). Direct first extracellular loop of the FMLP receptor played an important role in ligand binding (29) . Since this receptor domain appeared to play a critical role in ligand binding, it was of interest to determine if changes in the structural composition of the C-terminal or N-terminal end of this peptide altered ligand binding to the 68-kDa protein. By SDS-PAGE, autoradiography, and laser densitometric analysis, each of the peptides was tested for the ability to inhibit binding of radiolabeled photoaffinity-conjugated FMLP (125I-PAL) to solubilized neutrophil membranes (major protein species of 68 kDa). As previously reported, peptide 2 exhibited the strongest inhibition (81%) of ligand binding to the 68-kDa protein (31) . Substitution of glycine residues in the C-terminal portion of peptide 2 (peptide 2b) resulted in a 69% inhibition of ligand binding to the 68-kDa protein, whereas glycine residue substitutions in the N-terminal portion (peptide 2a) showed a large reduction in inhibitory activity (22%). Peptides 2e (intracellu- Densitometer analysis of the autoradiograph from an SDS-10% PAGE gel which examined ligand binding to the 68-kDa neutrophil membrane protein in the presence of synthetic peptides. Samples of solubilized neutrophil membranes (30 jxg) were exposed to 200-,uM concentrations of the peptides, photolabeled with 1251I-PAL, subjected to SDS-PAGE and autoradiography, and then analyzed on an LKB Ultroscan densitometer. Ligand binding was quantitated by using the Gel Scan XL software program, which calculated the area under the peak generated from the intensity of the autoradiograph signal. Lane 1, '25I-PAL only; lane 2, peptide 2 (aa residues 84 to 100); lane 3, peptide 2d (aa residues 84 to 100, randomly arranged); lane 4, peptide 2i (peptide 2d amino acid sequence with a glycine substitution for the arginine residue); lane 5, peptide 2j (peptide 2d amino acid sequence with glycine substitutions for the arginine and both lysine residues). Refer to Table 1 for structural clarification. lar aa residues 51 to 62) and 2f (transmembrane aa residues 72 to 83) showed no measurable ability to inhibit ligand binding to the 68-kDa protein. These results suggested that the Nterminal end of the first extracellular loop is a major contributor to ligand binding.
After localizing ligand-binding activity to the N-terminal region of the first extracellular loop of the FMLP receptor, it was of interest to further characterize the specificity of the activity of peptide 2 (the original 17-aa residues making up the first extracellular domain of the FMLP receptor). To accomplish this, we synthesized a peptide (peptide 2d) that consisted of a random rearrangement of peptide 2 residues which should act as a negative control. However, this randomly arranged peptide showed inhibition of ligand binding to the 68-kDa protein that was actually greater than that shown by peptide 2. This was surprising since it was hypothesized that a random peptide would have no activity. It has been suggested that FMLP binds to a pocket in the receptor which is predominantly hydrophobic and that FMLP "contacts" certain amino acid residues in the hydrophobic pocket (4, 16) . These contacts include a positively charged region, presumably interacting with a methionine residue, and a hydrophobic area likely to be interacting with the phenylalanine aromatic ring. Furthermore, numerous studies have implicated charged residues, particularly arginine, as playing a critical role in receptor-ligand binding (9, 10, 24) . Since peptide 2 contained a number of charged residues, this led us to investigate whether histidine, arginine, and/or lysine played a role(s) in ligand binding to the FMLP receptor. This was accomplished by making glycine substitutions for the individual charged moieties in peptide 2, as well as in the random peptide (peptide 2d). Examining His-90 in the first extracellular loop was interesting for two reasons. Not only is this charged residue the only histidine on the extracellular portion of the receptor, but also it has been reported that blocking these residues on neutrophil membranes with diethylpyrocarbonate could inhibit the binding of FMLP to such membranes, thus suggesting that histidine may be a necessary residue for FMLP binding to the receptor (36) . To investigate this issue, we synthesized a peptide (peptide 2c) which was identical to peptide 2 except for the replacement of His-90 with Gly-90. This substitution had no effect on ligand binding; i.e., the inhibitory activity of this peptide to the 68-kDa neutrophil protein as well as its direct ligand-binding characteristics remained unchanged regardless of whether there was a histidine or a glycine residue at position 90. Since this is the only histidine residue in the extracellular portion of the receptor molecule, it is possible that, although such a residue may not play a direct role in ligand binding, agents which react with it may indirectly affect this extracellular loop, thus interfering with binding.
Substitution of Gly-84 for Arg-84 resulted in a decrease in the inhibitory activity of peptide 2. When both Arg-84 and Lys-85 were replaced by glycine residues, a large reduction in peptide 2 inhibitory activity occurred. A similar result was found for both of the random peptides; i.e., substituting for the charged arginine and lysine residues in the randomly arranged peptide resulted in a total abrogation of inhibitory activity. The fact that inhibitory activity was lost even when the arginine and lysine residues in the random peptide were replaced suggests that the charged moieties on the first extracellular loop of the FMLP receptor may function as important contacts in receptor-ligand interactions, regardless of their orientation. This effect cannot be attributed solely to the effects of polycationic substances since poly-L-arginine and poly-L-lysine had no effect on ligand binding to the FMLP receptor component.
The seven-transmembrane-domain structure proposed for the FMLP receptor is similar to the structure of the ,-adrenergic, G-protein-coupled receptor (5, 27) . It has been reported that ligand binding to the P-adrenergic receptor occurs in the region of the second and third transmembrane regions (14, 37) . Our previous studies have shown that the FMLP ligand binds strongest directly to peptide 2 (31) , which is the extracellular loop (aa residues 84 to 100) between the second and third transmembrane domains of the FMLP receptor (no binding was observed for synthetic peptides to transmembrane regions in this area). Concomitantly, the strongest inhibition of ligand binding (81%) to neutrophil membrane proteins occurs with the same peptide. Our synthetic peptide studies which altered the C-terminal end of this loop, leaving the N-terminal end intact, showed a small decrease (69%) in inhibitory activity of ligand binding to the 68-kDa protein compared with the decrease seen with peptide 2 (81%). Concomitantly, alterations in the N-terminal end of this loop, leaving the Cterminal end intact, demonstrated a large decrease (22%) in inhibitory activity. Furthermore, glycine substitutions for arginine and lysine residues on the original, intact, first extracellular loop peptide and the randomly arranged peptide of this region implicated these residues as playing critical roles in binding. The first two residues (Arg-84 and Lys-85) of the N-terminal portion of the first extracellular loop are charged residues. This area not only has been implicated in ligand binding as a result of our N-terminal substitution studies but also contains the necessary features needed for ligand binding as proposed by Freer et al. (16) . Recently, Quehenberger et al. (30) reported a large decrease in ligand-binding affinity when a chimeric molecule was made in which the first extracellular loop of the FMLP receptor was replaced with the corresponding region from a 69% homologous granulocyte receptor (FPR2). The FPR2 receptor contains substitutions of nonpolar amino acids for the charged residues Arg-84 and Lys-85. Furthermore, a recombinant truncated FMLP receptor in an Escherichia coli expression system which lacked the first 86 residues of the full-length molecule was constructed. This mutant construct, which did not contain Arg-84 and Lys-85, failed to demonstrate specific ligand binding, whereas the full-length receptor protein did (21) . Our 
